Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor-Positive Metastatic Breast Cancer
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Frequent neutropenia hinders uninterrupted palbociclib treatment in patients with hormone receptor (HR)–positive breast cancer. We compared the efficacy outcomes in multicenter cohorts of patients with metastatic breast cancer (mBC) receiving palbociclib following conventional dose modification or limited modified schemes for afebrile grade 3 neutropenia. Materials and Methods Patients with HR-positive, human epidermal growth factor receptor 2–negative mBC (n=434) receiving palbociclib with letrozole as first-line therapy were analyzed and classified based on neutropenia grade and afebrile grade 3 neutropenia management as follows: group 1 (maintained palbociclib dose, limited scheme), group 2 (dose delay or reduction, conventional scheme), group 3 (no afebrile grade 3 neutropenia event), and group 4 (grade 4 neutropenia event). The primary and secondary endpoints were progression-free survival (PFS) between groups 1 and 2 and PFS, overall survival, and safety profiles among all groups. Results During follow-up (median 23.7 months), group 1 (2-year PFS, 67.9%) showed significantly longer PFS than did group 2 (2-year PFS, 55.3%; p=0.036), maintained across all subgroups, and upon adjustment of the factors. Febrile neutropenia occurred in one and two patients of group 1 and group 2, respectively, without mortality. Conclusion Limited dose modification for palbociclib-related grade 3 neutropenia may lead to longer PFS, without increasing toxicity, than the conventional dose scheme.
Abstract
Purpose Frequent neutropenia hinders uninterrupted palbociclib treatment in patients with hormone receptor (HR)–positive breast cancer. We compared the efficacy outcomes in multicenter cohorts of patients with metastatic breast cancer (mBC) receiving palbociclib following conventional dose modification or limited modified schemes for afebrile grade 3 neutropenia. Materials and Methods Patients with HR-positive, human epidermal growth factor receptor 2–negative mBC (n=434) receiving palbociclib with letrozole as first-line therapy were analyzed and classified based on neutropenia grade and afebrile grade 3 neutropenia management as follows: group 1 (maintained palbociclib dose, limited scheme), group 2 (dose delay or reduction, conventional scheme), group 3 (no afebrile grade 3 neutropenia event), and group 4 (grade 4 neutropenia event). The primary and secondary endpoints were progression-free survival (PFS) between groups 1 and 2 and PFS, overall survival, and safety profiles among all groups. Results During follow-up (median 23.7 months), group 1 (2-year PFS, 67.9%) showed significantly longer PFS than did group 2 (2-year PFS, 55.3%; p=0.036), maintained across all subgroups, and upon adjustment of the factors. Febrile neutropenia occurred in one and two patients of group 1 and group 2, respectively, without mortality. Conclusion Limited dose modification for palbociclib-related grade 3 neutropenia may lead to longer PFS, without increasing toxicity, than the conventional dose scheme.
참고문헌 (24)
- Finn RS, "Palbociclib and letrozole in advanced breast cancer", N Engl JMed, 375, pp.1925~1936 (2016)
- Cristofanilli M, "Overall survival(OS)with palbociclib(PAL)+fulvestrant(FUL)in women with hormone receptor–positive(HR+), human epidermal growth factor receptor 2–negative(HER2–)advanced breast cancer(ABC) : updated analysesfrom PALOMA-3", J Clin Oncol, 39(15 Suppl), pp.1000~ (2021)
- Hortobagyi GN, "Ribociclib as first-line therapy for HR-positive, advanced breast cancer", N Engl J Med, 375, pp.1738~1748 (2016)
- Slamon DJ, "Phase III randomized study of ribociclib andfulvestrant in hormone receptor-positive, human epidermalgrowth factor receptor 2-negative advanced breast cancer : MONALEESA-3", J Clin Oncol, 36, pp.2465~2472 (2018)
- Sledge GW Jr, "The effect of abemaciclib plus fulvestrant on overall survivalin hormone receptor-positive, ERBB2-negative breast cancerthat progressed on endocrine therapy-MONARCH 2 : a randomized clinical trial", JAMA Oncol, 6, pp.116~124 (2020)
- Goetz MP, "MONARCH 3 : abemaciclib as initial therapyfor advanced breast cancer", J Clin Oncol, 35, pp.3638~3646 (2017)
- Im SA, "Overall survival with ribociclib plus endocrine therapy inbreast cancer", N Engl J Med, 381, pp.307~316 (2019)
- Mayer EL, "Palbociclib with adjuvant endocrinetherapy in early breast cancer(PALLAS) : interim analysis ofa multicentre, open-label, randomised, phase 3 study", LancetOncol, 22, pp.212~222 (2021)
- Johnston SR, "Abemaciclib combined with endocrine therapy for theadjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer(monarchE)", J Clin Oncol, 38, pp.3987~3998 (2020)
- Cunningham NC, "Understanding divergent trialresults of adjuvant CDK4", 6 inhibitors for early stage breastcancer, 2021, pp.39, 307~309
- O’Leary B, "Treating cancer with selectiveCDK4", 6 inhibitors, 2016, pp.13, 417~430
- Hu W, "Mechanistic investigation of bone marrow suppression associated with palbociclib and its differentiation fromcytotoxic chemotherapies", Clin Cancer Res, 22, pp.2000~2008 (2016)
- Finn RS, "PD 0332991, a selective cyclin D kinase 4", 6 inhibitor, preferentially inhibits proliferation of luminal estrogenreceptor-positive human breast cancer cell lines in vitro, 2009, pp.11, R77~
- Ham A, "Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer", Breast Cancer Res Treat, 183, pp.107~116 (2020)
- IBRANCE (palbociclib), "Summary of product characteristics" (2018), Pfizer Ltd
- Berek JS, "Safety and dose modification for patientsreceiving niraparib", Ann Oncol, 29, pp.1784~1792 (2018)
- Sun W, "Characterization of neutropenia in advan-ced cancer patients following palbociclib treatment using apopulation pharmacokinetic-pharmacodynamic modelingand simulation approach", J Clin Pharmacol, 57, pp.1159~1173 (2017)
- Budman DR, "Dose and dose intensity as determinantsof outcome in the adjuvant treatment of breast cancer. TheCancer and Leukemia Group B", J Natl Cancer Inst, 90, pp.1205~1211 (1998)
- Early Breast Cancer Trialists’ Collaborative Group(EBCTCG), "Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling : a patient-levelmeta-analysis of 37 298 women with early breast cancer in 26randomised trials", Lancet, 393, pp.1440~1452 (2019)
- Veitch Z, "Impact of cumulative chemotherapy dose on survivalwith adjuvant FEC-D chemotherapy for breast cancer", J NatlCompr Canc Netw, 17, pp.957~967 (2019)
- Shirotake S, "Impact of second-line targeted therapy dose intensityon patients with metastatic renal cell carcinoma", Clin Genitourin Cancer, 14, pp.e575~83 (2016)
- Di Leo A, "Results of the CONFIRM phase IIItrial comparing fulvestrant 250 mg with fulvestrant 500 mgin postmenopausal women with estrogen receptor-positiveadvanced breast cancer", J Clin Oncol, 28, pp.4594~4600 (2010)
- Turner NC, "Overall survival with palbociclib and fulvestrant in advanced breast cancer", N Engl J Med, 379, pp.1926~1936 (2018)
- Im SA, "Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer : results from the phase III, randomized PALOMA-2 study", J Glob Oncol, 5, pp.1~19 (2019)